Pharma Focus Europe

IRLAB Embarks on Development Collaboration for IRL757, a Promising Treatment for Apathy

Wednesday, May 08, 2024

IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A) has entered into a collaboration with the McQuade Center for Strategic Research and Development, LLC (MSRD), a part of the Otsuka pharmaceutical family, to develop innovative treatments for Parkinson’s disease. The partnership will focus exclusively on advancing IRLAB's new drug candidate, IRL757, aiming to address apathy in Parkinson’s and other neurological conditions through clinical proof-of-concept.

MSRD, known for its initiatives in early-stage mental illness and renal disorder treatments, will collaborate with IRLAB to develop IRL757, including conducting specified clinical studies. These studies may help identify safety and efficacy signals for Parkinson’s and Alzheimer’s diseases. IRLAB has initiated the Phase I program for IRL757, supported by funding from The Michael J. Fox Foundation, with recruitment expected to start in Q2, 2024.

Under the collaboration, IRLAB stands to receive an upfront payment of 3 million USD and up to an additional 5.5 million USD based on reaching certain developmental milestones. MSRD will finance the drug development activities throughout the agreement term, except for the Phase I program, which is funded by The Michael J. Fox Foundation.

Additionally, the agreement allows MSRD the option to expand the collaboration based on specific triggers, subject to negotiations for a new agreement. If expansion does not occur, MSRD may receive low single-digit percentage royalty payments under certain circumstances.

MSRD, expressed excitement about the collaboration, emphasizing MSRD's dedication to identifying transformative early-stage opportunities in mental health treatment.

IRLAB, shared enthusiasm about partnering with MSRD and Otsuka, recognizing their expertise and commitment to advancing innovative treatments for neurological disorders.

IRL757, the focus of the collaboration, targets apathy in Parkinson’s disease and other neurological conditions, representing a significant unmet medical need affecting over 20 million individuals in the U.S. and Europe. IRL757 has shown promising outcomes in preclinical models, suggesting efficacy by reversing disruptions in nerve signaling believed to underlie apathy in neurological disorders. All preclinical prerequisites for Phase I have been fulfilled, positioning IRL757 as a promising candidate for effective apathy treatment.



Thermo Fisher Scientific - mRNA ServicesWorld Orphan Drug Congress 2024World Vaccine Congress Europe 2024Advanced Therapies USA 2024